Camelot Portfolios, LLC Nektar Therapeutics Transaction History

Camelot Portfolios, LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 Apr 20, 2022	SELL	$4.16 - $13.72 $42,024 - $138,599	-10,102 Closed	0 $0
Q4 2021 Jan 04, 2022	BUY	$10.83 - $18.41 $109,404 - $185,977	10,102 New	10,102 $136,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $242M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Camelot Portfolios, LLC, based on Form 13F filings with the SEC.

Stay updated on Camelot Portfolios, LLC with notifications on news.